SUMER ANDERSON: Open Payments
NPI 1992071559 · SANDY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,061 in 97 payments from 20 companies in 2025. Trend: 2023 $1,609 · 2024 $2,236 · 2025 $2,061
Food & beverage: $2,061
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $308 |
| Janssen Pharmaceuticals, Inc | 9 | $206 |
| Neurocrine BioSciences, Inc. | 9 | $195 |
| Alkermes, Inc. | 7 | $182 |
| Vanda Pharmaceuticals Inc. | 6 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $159 |
| Otsuka America Pharmaceutical, Inc. | 7 | $148 |
| Tris Pharma Inc | 5 | $106 |
| Lundbeck LLC | 4 | $79 |
Products named: VRAYLAR, REXULTI, INGREZZA, ARISTADA, FANAPT, SPRAVATO, TRINTELLIX, CAPLYTA.
Industry payments across UT — which companies pay providers there.
